PUBLISHER: DataM Intelligence | PRODUCT CODE: 1345424
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1345424
Global Gene Expression Analysis Market reached US$ 4.5 billion in 2022 and is expected to reach US$ 8.6 billion by 2030 growing with a CAGR of 8.7% during the forecast period 2023-2030.
Gene expression analysis is the study of how genes are transcribed to synthesize functional gene products, functional RNA species, or protein products. The study of gene regulation provides insights into normal cellular processes, such as differentiation and abnormal or pathological processes. Gene expression analysis provides valuable insight into the role of differential gene expression in normal biological and disease processes and in the identification and verification of biomarker signatures.
Real-time PCR is the gold-standard technique for the verification of differential gene expression profiles. Transcriptome sequencing by next-generation sequencing enables the discovery of differentially expressed genes using a hypothesis-neutral approach. The advancements in gene expression profiling lead to better outcomes.
Furthermore, the Laser capture microdissection (LCM) and microarray technology are providing the next revolution in the study of gene expression. Integration of artificial intelligence and machine learning give better outcomes as the logarithms are trained to provide accurate data during the entire procedure. These are the factors which are expected to drive the market in the forthcoming period.
The growing technological advancements such as NGS and molecular services are boosting the demand for gene expression services. Additionally, the development of genomic databases, increased government funding for genomics, and personalized medicine growth will likely drive the market. Increasing government funding for genomics is one of the major factors leading to the development of the gene expression analysis market.
In March 2023, Illumina released its new Connected Insights, cloud-based software that provides tertiary analysis for clinical next-generation sequencing (NGS) data. Connected Insights is the next step in creating a fully integrated software ecosystem that scales with the pace of discovery across NGS applications.
Application of AI/ML algorithms for statistical and predictive analyses using whole genome sequencing for gene variants, and RNA-seq and microarrays for gene expression is observed these days as the outcome is accurate and more reliable for profiling. In gene expression microarray data, machine learning-based feature selection approaches like gene selection approaches will help to select the required genes from the pool.
On June 1, 2023, Illumina Inc., a global leader in DNA sequencing and array-based technologies, launched the new PrimateAI-3D, an artificial intelligence (AI) algorithm that predicts with unprecedented accuracy disease-causing genetic mutations in patients. PrimateAI-3D addresses a critical challenge facing the successful implementation of personalized genomic medicine. It also greatly improved the accuracy of genetic risk prediction.
The high cost associated with sequencing posed a significant challenge to market growth in the last decade. In 2003, the first human genome sequenced by the Human Genome Project required ~USD 2.7 billion in funding. However, several technological developments have taken place in the field of genomics, which were aimed at increasing the speed and reducing the expenses associated with sequencing.
The NHGRI (National Human Genome Research Institute, US) has tracked the sequencing costs at its various funded genome sequencing centers for many years and estimated the cost of genome sequencing in the years following the Human Genome Project. Based on this data, the NHGRI estimated that in 2006, it would have likely cost over USD 20-25 million to generate a finished human genome sequence, while by late 2015, the price to develop a high-quality whole human genome sequence draft had fallen below USD 1,500. The cost to generate a whole-exome sequence was generally below USD 1,000.
The global gene expression analysis market is segmented based on product type, technique, application, end-user and region.
RNA Sequencing is expected to hold the largest market share as the technique uses next-generation sequencing (NGS), AI to reveal the presence and quantity of RNA in a biological sample. With the advent of machine learning and other technological advancements, gene expression analysis accuracy has increased.
In March 2023, Alithea Genomics, a Lausanne-based start-up that specializes in high-throughput RNA sequencing, secured a CHF 500,000 Tech Growth loan from the Foundation for Technological Innovation (FIT). RNA sequencing is a valuable tool in biomedical research, allowing scientists to examine gene expression, discover new biomarkers, and develop new drugs. Alithea Genomics aims to address this challenge with its proprietary technology, Bulk RNA Barcoding followed by sequencing (BRB-seq), which can prepare thousands of RNA samples for sequencing in a single tube, unlike standard RNA-seq sample preparation
North America is dominating the global gene expression analysis market, with the United States accounting as the major contributor to the market. The United States spends the most compared to other countries on genomics research, corresponding to 40% of worldwide public funding.
Citizens and taxpayers of several countries have funded much of the research and have expectations about access to the resulting information and knowledge. While access to knowledge gained from all publicly funded research is desired, access is essential for fields that have a broad social impact and stimulate public dialogue. Innovate UK has up to £5 million to support capital investment in equipment that increases the UK's capacity to produce and commercialize genomic analysis technologies.
Most of the major key players are based in North America such as Illumina, Inc., Quest Diagnostics Incorporated, Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Agilent Technologies, Luminex Corporation, etc. are contributing to making this region the largest shareholder in gene expression analysis market. For instance, in Jan 2022, Illumina Inc. announced a multi-year agreement with Nashville Biosciences LLC to increase medicines development via large-scale genomics and also the formation of clinical-genomic resource that is pre-eminent with the help of Illumina's next-generation sequencing (NGS)
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global gene expression analysis market, as countries grappled with lockdowns, supply chain disruptions, and reduced economic activity. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting healthcare innovations worldwide. The COVID-19 pandemic severely disrupted global supply chains, affecting the transportation of raw materials to industries.
The focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. This diversion of resources and attention may have temporarily impacted the progress of genetic research and development activities. This has led to delays in the completion of trials and the availability of new diagnostic procedures and therapies, which has affected the market.
The major global players in the gene expression analysis market include: QIAGEN, Merck KGaA, Genscript Biotech Corporation, Bio-Rad Laboratories, Takara Bio Inc., Thermo Fisher Scientific, Inc., Promega Corporation, Agilent Technologies, Lonza Group Ltd., New England Biolabs Inc. among others.
The global gene expression analysis market report would provide approximately 53 tables, 54 figures, and 195 Pages.
LIST NOT EXHAUSTIVE